# Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

> **NCT02632708** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 153 (actual)

## Conditions studied

- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Untreated AML
- AML Arising From Myelodysplastic Syndrome (MDS)
- AML Arising From Antecedent Hematologic Disorder (AHD)
- AML Arising After Exposure to Genotoxic Injury

## Interventions

- **DRUG:** AG-120
- **DRUG:** AG-221
- **DRUG:** cytarabine
- **DRUG:** daunorubicin
- **DRUG:** idarubicin
- **DRUG:** mitoxantrone
- **DRUG:** etoposide

## Key facts

- **NCT ID:** NCT02632708
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-12-31
- **Primary completion:** 2018-12-13
- **Final completion:** 2026-07-24
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2025-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02632708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02632708, "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02632708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*